Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus XELOX or SOX as adjuvant therapy for locally advanced gastric cancer
ChiCTR2600124567Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- May 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in gastric cancer (GC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Disease-free survival. Started May 2026; status: recruiting.
02
Drugs
envafolimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2600124567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124567.